- Home
- CRSP
as 03-25-2025 11:32am EST
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
| Founded: | 2013 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 3.4B | IPO Year: | 2016 |
| Target Price: | $74.35 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.52 - $73.09 | Next Earning Date: | 05-07-2025 |
| Revenue: | $37,314,000 | Revenue Growth: | -89.95% |
| Revenue Growth (this year): | 49.76% | Revenue Growth (next year): | 257.28% |
Stock Insider Trading Activity of CRISPR Therapeutics AG (CRSP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kulkarni Samarth | CRSP | Chief Executive Officer | Mar 20 '25 | Sell | $41.23 | 10,031 | $413,578.13 | 195,085 | |
| Prasad Raju | CRSP | Chief Financial Officer | Mar 20 '25 | Sell | $41.23 | 2,197 | $90,582.31 | 16,767 | |
| Bruno Julianne | CRSP | Chief Operating Officer | Mar 20 '25 | Sell | $41.23 | 1,714 | $70,668.22 | 10,544 | |
| Prasad Raju | CRSP | Chief Financial Officer | Mar 14 '25 | Sell | $41.80 | 3,762 | $157,251.60 | 16,767 | |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Mar 10 '25 | Sell | $42.87 | 14,435 | $616,348.50 | 195,085 | |
| Bruno Julianne | CRSP | Chief Operating Officer | Mar 10 '25 | Sell | $42.87 | 1,388 | $59,049.96 | 10,544 | |
| Greene John | CRSP | Director | Feb 26 '25 | Buy | $44.85 | 7,000 | $313,947.90 | 7,000 | |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Feb 19 '25 | Sell | $55.21 | 18,360 | $1,013,563.80 | 195,085 | |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Feb 18 '25 | Sell | $53.93 | 18,568 | $1,006,580.40 | 195,085 | |
| Bruno Julianne | CRSP | Chief Operating Officer | Feb 18 '25 | Sell | $52.80 | 333 | $17,582.40 | 10,544 |
Latest CRISPR Therapeutics AG News
CRSP Breaking Stock News: Dive into CRSP Ticker-Specific Updates for Smart Investing
Motley Fool
4 days ago
2 Beaten-Down Stocks to Buy on the Dip
Zacks
5 days ago
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
Investor's Business Daily
5 days ago
As The Biotech Sector Remains Strong, Vertex Stock Trades Near Buy Point
Zacks
6 days ago
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
Motley Fool
7 days ago
2 No-Brainer Biotech Stocks to Buy Right Now
Insider Monkey
7 days ago
Is CRISPR Therapeutics (CRSP) One of the Most Shorted Stocks in 2025?
Zacks
7 days ago
CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?
Insider Monkey
7 days ago
CRISPR Therapeutics AG (CRSP): A Bull Case Theory
Compare CRSP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRSP CRISPR Therapeutics AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.